Executive Committee
The Executive Committee makes time-sensitive decisions in between Board meetings. The decisions are ratified at the next full Board meetings.
Members of the Committee
Louise is the Lead Marketing, Patient Support Programs & Advocacy at Shionogi Canada Inc. She is an accomplished Pharma Leader with >25 years executive experience and track record of achievements in Complex Specialty Pharma. Recognized as a change agent, she brings unique perspectives gained from her broad commercial & patient access experience, including in setting up Canadian Operations.
Antonia is a Managing Director on the investment banking team at Bloom Burton where she leads the firm’s scientific ideation team and management consulting practice, providing clients with advice on scientific, clinical and capital markets strategy. Dr. Borovina has been with Bloom Burton since 2014 and has held several positions in the firm, most recently as an analyst on the equity research team, where she researched publicly traded healthcare companies and made investment recommendations. Prior to joining Bloom Burton, she gained business development experience while working for GeneYouIn, a direct-to-consumer genetic testing startup. Dr. Borovina currently serves on the Emerging Companies Advisory Board of BIOTECanada, the national biotechnology industry association.
Rika is a highly accomplished veterinarian with a diverse academic and professional background. She obtained her Doctor of Veterinary Medicine degree from the University of Ghent, Belgium, and pursued further studies, including internships and research assistantships. Dr. Jolie’s extensive academic journey includes a residency in Swine Medicine and a PhD focusing on airborne contaminants’ impact on swine respiratory health. Over the past 12+ years, she has held significant roles at Pfizer Animal Health and Merck Animal Health, showcasing her expertise in the field and culminating in the completion of an Executive MBA. At Merck Animal Health, she has led pivotal roles, including heading the Global Swine division, shaping strategic direction and ensuring product alignment to meet global market needs.
Elizabeth is the CEO of GlycoNet. She was involved in the GlycoNet initiative since the Letter of Intent stage and served as the Associate Director, Business for the Alberta Glycomics Centre from 2007–2015. Prior to her position with the Centre, she worked as a manager of large-scale and multi-institutional projects with Genome Prairie. In addition to her PhD in biochemistry, Elizabeth has an MBA in biotechnology management.
Observer
Warren is a Professor from the Department of Biological Sciences at the University of Alberta. The Wakarchuk lab investigates the structure and function of the enzymes which make and degrade various glycoconjugates. This work has been enabling the chemo-enzymatic synthesis of bioactive glycoconjugates both in the laboratory and for industrial projects. The Wakarchuk lab has expertise with both mammalian and bacterial carbohydrate active enzymes for glycan remodelling applications.
Terms of Reference
View Terms of Reference (PDF)
Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147
Subscribe to GlycoNet’s Newsletter
© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.